ArticleInternational journal of pharmaceutics2010
In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice.
Article in International journal of pharmaceutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 92 citations in OpenAlex.
- Tandem-Mass-Tag Based Proteomic Analysis Facilitates Analyzing Critical Factors of Porous Silicon Nanoparticles in Determining Their Biological Responses under Diseased Condition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Modeling of Nanotherapy Response as a Function of the Tumor Microenvironment: Focus on Liver Metastasis.Frontiers in bioengineering and biotechnology · 2020Review
- Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles.Acta biomaterialia · 2019Article
- Visible Light Assisted Organosilane Assembly on Mesoporous Silicon Films and Particles.Materials (Basel, Switzerland) · 2019Article
- Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid.Contrast media & molecular imaging · 2019Article
- Generation of Well-Defined Micro/Nanoparticles via Advanced Manufacturing Techniques for Therapeutic Delivery.Materials (Basel, Switzerland) · 2018Review
- Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.Cancer letters · 2017Article
- Post-nano strategies for drug delivery: Multistage porous silicon microvectors.Journal of materials chemistry. B · 2017Article
- Engineered nanomaterial-induced lysosomal membrane permeabilization and anti-cathepsin agents.Journal of toxicology and environmental health. Part B, Critical reviews · 2017Review
- In vivo toxicologic study of larger silica nanoparticles in mice.International journal of nanomedicine · 2017Article
- A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.Pharmacological research · 2016Article
- Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions.Nanoscale · 2016Article
- Redirecting Transport of Nanoparticle Albumin-Bound Paclitaxel to Macrophages Enhances Therapeutic Efficacy against Liver Metastases.Cancer research · 2016Article
- Multistage vector (MSV) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Mapping Local Cytosolic Enzymatic Activity in Human Esophageal Mucosa with Porous Silicon Nanoneedles.Advanced materials (Deerfield Beach, Fla.) · 2015Article
- Biodegradable nanoneedles for localized delivery of nanoparticles in vivo: exploring the biointerface.ACS nano · 2015Article
- Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors.Nanoscale · 2014Article
- In situ synthesis of peptide nucleic acids in porous silicon for drug delivery and biosensing.Bioconjugate chemistry · 2014Article
- pH-responsive drug delivery system based on hollow silicon dioxide micropillars coated with polyelectrolyte multilayers.Nanoscale research letters · 2014Article
- Cefazolin-loaded mesoporous silicon microparticles show sustained bactericidal effect against Staphylococcus aureus.Journal of tissue engineering · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Porous silicon (pSi) is being extensively studied as an emerging material for use in biomedical applications, including drug delivery, based on the biodegradability and versatile chemical and biophysical properties. We have recently introduced multistage nanoporous silicon microparticles (S1MP) designed as a cargo for nanocarrier drug delivery to enable the loaded therapeutics and diagnostics to sequentially overcome the biological barriers in order to reach their target. In this first report on biocompatibility of intravenously administered pSi structures, we examined the tolerability of negatively (-32.5±3.1mV) and positively (8.7±2.5mV) charged S1MP in acute single dose (10(7), 10(8), 5×10(8) S1MP/animal) and subchronic multiple dose (10(8) S1MP/animal/week for 4 weeks) administration schedules. Our data demonstrate that S1MP did not change plasma levels of renal (BUN and creatinine) and hepatic (LDH) biomarkers as well as 23 plasma cytokines. LDH plasma levels of 145.2±23.6, 115.4±29.1 vs. 127.0±10.4; and 155.8±38.4, 135.5±52.3 vs. 178.4±74.6 were detected in mice treated with 10(8) negatively charged S1MP, 10(8) positively charged S1MP vs. saline control in single and multiple dose schedules, respectively. The S1MPs did not alter LDH levels in liver and spleen, nor lead to infiltration of leukocytes into the liver, spleen, kidney, lung, brain, heart, and thyroid. Collectively, these data provide evidence of a safe intravenous administration of S1MPs as a drug delivery carrier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.